ClinicalTrials.gg
CompletedNCT00372697Updated May 17, 2011Results posted

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

A Phase 3 interventional study of Octreotide acetate 30 mg suspension in Acromegaly, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-05-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.

Enrollment
18th of 25
28 · median 56
Started
2005
the only one that year
Phase 3
12 of 25
1 open now
Registered
7th of 25
by date
Lead sponsor
5 of 25
Novartis Pharmaceuticals

Among the 25 studies testing octreotide in Acromegaly, this one is the 18th largest by enrollment, is the only one that started in 2005, is one of 12 in phase 3, and was the 7th registered.

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

Browse Acromegaly studies →

Open to participants now

1 of the 25 studies testing octreotide in Acromegaly is open now. Recruiting first, the newest first:

About octreotide

Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing octreotide in Acromegaly, or all of them as a file.
02

Study summary

This study evaluated the safety and efficacy of an increased frequency of octreotide acetate injections or an increase in dose in partially responsive acromegalic patients with persistently uncontrolled disease.

03

Conditions studied

  • Acromegaly

Browse trials for

Keywords

  • acromegaly
  • octreotide acetate
  • partial responder patients
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Written voluntary .
  • Patients with biochemically documented active acromegaly who are currently receiving somatostatin-analogues in a conventional treatment regimen (octreotide up to 30 mg/28 days; lanreotide up to 120 mg/28 days) for at least 6 months.
  • Patients with uncontrolled disease defined as patients with a decrease of baseline levels of growth hormone (GH) ≥ 50% during treatment with somatostatin-analogues in a conventional regimen (sandostatin up to 30 mg/28 days; lanreotide up to 120 mg/28 days) for at least 6 months.
  • Baseline (mean of 3 samples) GH level > 2 µg/L.
  • Insulin-like Growth Factor I (IGF-I) levels above the for age and gender.

Other protocol-defined inclusion/exclusion criteria applied to the study.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Octreotide 30 mg every 21 days

    Patients received octreotide 30 mg every 21 days intramuscularly (im) for 6 months, a total of 8 doses. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.

    Drug: Octreotide acetate 30 mg suspension

  • Experimental
    Octreotide 60 mg every 28 days

    Patients received octreotide 60 mg every 28 days intramuscularly (im) for 6 months, a total of 6 doses. Octreotide mg was administered as two 30 mg injections. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.

    Drug: Octreotide acetate 30 mg suspension

Interventions

  • Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.

    Also known as: Sandostatin LAR

06

What researchers measure

Primary outcomes

  1. Change in Growth Hormone (GH) Level From Screening to End of Study (Week 24)

    Growth hormone (GH) level was the average value measured in 3 blood samples collected at 15 minute intervals at each visit. GH was measured with an automated immunometric assay in a central laboratory.

    Time frame: Screening to end of study (Week 24)

  2. Change in Insulin-like Growth Factor 1 (IGF-1) Level From Screening to End of Study (Week 24)

    Insulin-like growth factor 1 (IGF-1) level was measured in a blood sample with an automated immunometric assay in a central laboratory.

    Time frame: Screening to end of study (Week 24)

Secondary outcomes

  1. Change in Tumor Volume From Screening to End of Study (Week 24)

    A pre-treatment magnetic resonance image (MRI) assessment of the pituitary area was required within 12 weeks prior to Screening as a baseline evaluation. A second MRI was performed at the end of the study (Week 24). All MRIs were performed according to protocol-defined guidelines. The tumor volume (mm\^3) was calculated from measurements obtained in 3 axes from the MRI images.

    Time frame: Screening to end of study (Week 24)

  2. Percentage of Participants With > 20% Tumor Shrinkage From Screening to End of Study (Week 24)

    A pre-treatment magnetic resonance image (MRI) assessment of the pituitary area was required within 12 weeks prior to Screening as a baseline evaluation. A second MRI was performed at the end of the study (Week 24). All MRIs were performed according to protocol-defined guidelines. The tumor volume (mm\^3) was calculated from measurements obtained in 3 axes from the MRI images.

    Time frame: Screening to end of study (Week 24)

  3. Percentage of Participants Asymptomatic for Acromegaly Symptoms at Week 12 and End of Study (Week 24)

    The investigator asked the participant to score the following symptoms of acromegaly: Headache, perspiration, paresthesia, fatigue, osteoarthralgia, and carpal tunnel syndrome on a 5-point scale (0=absent; 1=mild; 2=moderate; 3=severe, but not disabling; 4=severe and disabling). The percentage of asymptomatic participants, ie, with a score of 0 for all symptoms, was calculated.

    Time frame: Week 12 and end of study (Week 24)

  4. Acromegaly Quality of Life (AcroQoL) Questionnaire Physical Scale Score at End of Study (Week 24)

    The AcroQoL contains 8 items on Physical aspects. Participants were asked to rate each item on a 1-5 Likert scale measuring either the frequency of occurrence (always, most of the time, sometimes, rarely, or never) or the degree of agreement (completely agree, moderately agree, neither agree nor disagree, moderately disagree, completely disagree). The score on the physical scale can range from 8-40. A higher score indicates better Quality of Life.

    Time frame: End of study (Week 24)

  5. Acromegaly Quality of Life (AcroQoL) Questionnaire Psychological Scale Score at End of Study (Week 24)

    The AcroQoL contains 14 items on Psychological aspects. Participants were asked to rate each item on a 1-5 Likert scale measuring either the frequency of occurrence (always, most of the time, sometimes, rarely, or never) or the degree of agreement (completely agree, moderately agree, neither agree nor disagree, moderately disagree, completely disagree). The score on the psychological scale ranges from 14-70. A higher score indicates better Quality of Life.

    Time frame: End of study (Week 24)

07

Results

Posted May 17, 2011

Participant flow

Participant flow — Overall Study
MilestoneOctreotide 30 mg Every 21 DaysOctreotide 60 mg Every 28 Days
Started1612
Completed1511
Not completed11
Withdrew: Protocol violation11

Outcome measures

PrimaryChange in Growth Hormone (GH) Level From Screening to End of Study (Week 24)

Growth hormone (GH) level was the average value measured in 3 blood samples collected at 15 minute intervals at each visit. GH was measured with an automated immunometric assay in a central laboratory.

Time frame:
Screening to end of study (Week 24)
Reported as:
Mean · µg/L
Change in Growth Hormone (GH) Level From Screening to End of Study (Week 24)
µg/LOctreotide 30 mg Every 21 DaysOctreotide 60 mg Every 28 Days
Change in Growth Hormone (GH) Level From Screening to End of Study (Week 24)-1.7 ± 9.9-2.1 ± 3.6
PrimaryChange in Insulin-like Growth Factor 1 (IGF-1) Level From Screening to End of Study (Week 24)

Insulin-like growth factor 1 (IGF-1) level was measured in a blood sample with an automated immunometric assay in a central laboratory.

Time frame:
Screening to end of study (Week 24)
Reported as:
Mean · µg/L
Change in Insulin-like Growth Factor 1 (IGF-1) Level From Screening to End of Study (Week 24)
µg/LOctreotide 30 mg Every 21 DaysOctreotide 60 mg Every 28 Days
Change in Insulin-like Growth Factor 1 (IGF-1) Level From Screening to End of Study (Week 24)-40.4 ± 180.2-135.0 ± 170.9
SecondaryChange in Tumor Volume From Screening to End of Study (Week 24)

A pre-treatment magnetic resonance image (MRI) assessment of the pituitary area was required within 12 weeks prior to Screening as a baseline evaluation. A second MRI was performed at the end of the study (Week 24). All MRIs were performed according to protocol-defined guidelines. The tumor volume (mm\^3) was calculated from measurements obtained in 3 axes from the MRI images.

Time frame:
Screening to end of study (Week 24)
Reported as:
Mean · mm^3
Change in Tumor Volume From Screening to End of Study (Week 24)
mm^3Octreotide 30 mg Every 21 DaysOctreotide 60 mg Every 28 Days
Change in Tumor Volume From Screening to End of Study (Week 24)15.9 ± 91.8-0.4 ± 21.0
SecondaryPercentage of Participants With > 20% Tumor Shrinkage From Screening to End of Study (Week 24)

A pre-treatment magnetic resonance image (MRI) assessment of the pituitary area was required within 12 weeks prior to Screening as a baseline evaluation. A second MRI was performed at the end of the study (Week 24). All MRIs were performed according to protocol-defined guidelines. The tumor volume (mm\^3) was calculated from measurements obtained in 3 axes from the MRI images.

Time frame:
Screening to end of study (Week 24)
Reported as:
Number · Percentage of participants
Percentage of Participants With > 20% Tumor Shrinkage From Screening to End of Study (Week 24)
Percentage of participantsOctreotide 30 mg Every 21 DaysOctreotide 60 mg Every 28 Days
Percentage of Participants With > 20% Tumor Shrinkage From Screening to End of Study (Week 24)14.3 ± 642611.1 ± 4211
SecondaryPercentage of Participants Asymptomatic for Acromegaly Symptoms at Week 12 and End of Study (Week 24)

The investigator asked the participant to score the following symptoms of acromegaly: Headache, perspiration, paresthesia, fatigue, osteoarthralgia, and carpal tunnel syndrome on a 5-point scale (0=absent; 1=mild; 2=moderate; 3=severe, but not disabling; 4=severe and disabling). The percentage of asymptomatic participants, ie, with a score of 0 for all symptoms, was calculated.

Time frame:
Week 12 and end of study (Week 24)
Reported as:
Number · Percentage of participants
Percentage of Participants Asymptomatic for Acromegaly Symptoms at Week 12 and End of Study (Week 24)
Percentage of participantsOctreotide 30 mg Every 21 DaysOctreotide 60 mg Every 28 Days
Week 1233.39.09
Week 2420.09.09
SecondaryAcromegaly Quality of Life (AcroQoL) Questionnaire Physical Scale Score at End of Study (Week 24)

The AcroQoL contains 8 items on Physical aspects. Participants were asked to rate each item on a 1-5 Likert scale measuring either the frequency of occurrence (always, most of the time, sometimes, rarely, or never) or the degree of agreement (completely agree, moderately agree, neither agree nor disagree, moderately disagree, completely disagree). The score on the physical scale can range from 8-40. A higher score indicates better Quality of Life.

Time frame:
End of study (Week 24)
Reported as:
Mean · Percent of maximum score
Acromegaly Quality of Life (AcroQoL) Questionnaire Physical Scale Score at End of Study (Week 24)
Percent of maximum scoreOctreotide 30 mg Every 21 DaysOctreotide 60 mg Every 28 Days
Acromegaly Quality of Life (AcroQoL) Questionnaire Physical Scale Score at End of Study (Week 24)67.9 ± 22.658.0 ± 21.8
SecondaryAcromegaly Quality of Life (AcroQoL) Questionnaire Psychological Scale Score at End of Study (Week 24)

The AcroQoL contains 14 items on Psychological aspects. Participants were asked to rate each item on a 1-5 Likert scale measuring either the frequency of occurrence (always, most of the time, sometimes, rarely, or never) or the degree of agreement (completely agree, moderately agree, neither agree nor disagree, moderately disagree, completely disagree). The score on the psychological scale ranges from 14-70. A higher score indicates better Quality of Life.

Time frame:
End of study (Week 24)
Reported as:
Mean · Percent of maximum score
Acromegaly Quality of Life (AcroQoL) Questionnaire Psychological Scale Score at End of Study (Week 24)
Percent of maximum scoreOctreotide 30 mg Every 21 DaysOctreotide 60 mg Every 28 Days
Acromegaly Quality of Life (AcroQoL) Questionnaire Psychological Scale Score at End of Study (Week 24)65.1 ± 19.972.1 ± 19.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Octreotide 30 mg Every 21 Days—0/16 (0%)3/16 (18.8%)
Octreotide 60 mg Every 28 Days—0/12 (0%)2/12 (16.7%)
Most frequent other events
Most frequent other events
EventOctreotide 30 mg Every 21 DaysOctreotide 60 mg Every 28 Days
DiarrhoeaGastrointestinal disorders1/162/12
FlatulenceGastrointestinal disorders2/160/12

Baseline characteristics

Age Continuous
Age Continuous(years)Octreotide 30 mg Every 21 DaysOctreotide 60 mg Every 28 DaysTotal
Mean51.3 ± 12.151.8 ± 15.751.5 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)Octreotide 30 mg Every 21 DaysOctreotide 60 mg Every 28 DaysTotal
Female10414
Male6814
08

Study locations

1 site
  • Novartis Investigative Site
    Brescia, Italy
09

References and documents

Publications

  • Mazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannavo S, Colao A, Cozzi R, De Marinis L, degli Uberti E, Grottoli S, Minuto F, Montini M, Spinello M, Giustina A. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol. 2011 Mar;164(3):341-7. doi: 10.1530/EJE-10-0811. Epub 2011 Jan 6. PubMed 21212103 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2006
First posted
Sep 7, 2006
Start
Dec 2005
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Results first posted
May 17, 2011
Last update
May 17, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00372697
First posted
Sep 7, 2006
Start date
Dec 2005
Primary completion
Oct 2007
Completion
Oct 2007
Results posted
May 17, 2011
Last update
May 17, 2011

Study contacts

Novartis
study chair · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion